Ascletis

Ascletis Pharma Inc. is a biotechnology company engaged in the research, development, manufacturing, marketing, and sale of pharmaceutical products primarily in Mainland China and internationally. The company specializes in therapies for viral infections and liver diseases, offering products such as Ganovo, a direct-acting antiviral for hepatitis C, and Pegasys, a pegylated interferon for hepatitis B and C. Its product pipeline includes ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor poised for Phase II trials targeting non-alcoholic steatohepatitis, and ASC41, an oral THR-ß agonist for the same condition. Additionally, Ascletis is advancing therapies for HIV and liver cancer, with several products in clinical and pre-clinical stages. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to leverage both international innovation and local market efficiencies to establish a sustainable and profitable business model in the evolving pharmaceutical landscape.